Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme calls mipomersen, currently in Phase III, a blockbuster after gaining rights in potential $1.9 billion deal.